A simple and economical dual wavelength spectrophotometric method has been developed for the simultaneous estimation of Cilnidipine and Olmesartan Medoxomil in their tablet dosage form. The principle for dual wavelength method is "the absorbance difference between two points on the overlain spectra is directly proportional to the concentration of the component of interest". From the UV absorption spectrum of Cilnidipine, three wavelengths were selected, which were 282.99, 337.85 and 352.92 nm. At 352.92 nm only Cilnidipine has reasonable absorbance, so it was selected for the estimation of it from combination drug product. At these two wavelengths absorbance for Cilnidipine was found to be same i.e. absorbance difference was zero for any concentration, while for Olmesartan Medoxomil concomitantly increase in absorbance difference with increase in its concentration. So, 282.99 and 337.85 nm wavelengths were selected for the estimation of Olmesartan Medoxomil from its combination drug product. The method involved solving of an equation based on measurement of absorbances at two wavelengths 282.99 and 337.85 nm. Regression analysis of Beer's plots showed good correlation in concentration range of 10-60 µg/ml for Cilnidipine and 20-120 µg/ml for Olmesartan Medoxomil. The suitability of this method was for quantitative determination of Cilnidipine and Olmesartan Medoxomil was proved by validation and recovery study. The proposed method was found to be simple, rapid, economical, accurate and reproducible for the routine analysis of both drugs in tablet dosage forms.
Introduction

Cilnidipine (CIL) is chemically, O3-(2-methoxyethyl) O5-[(E)-3-phenylprop-2-enyl]
2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate. Cilnidipine is a dual blocker of L-type voltage-gated calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals that supply blood vessels. It possesses a slow onset, long lasting vasodilating effect. Olmesartan Medoxomil (OLME) is chemically (5-methyl-2-oxo-2H-1,3-dioxol-4-yl) methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5 yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate. It is angiotensin II receptor blocker. It blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in vascular smooth muscle.CIL is not official in any pharmacopoeia and OLME is official in USP and BP. Both drugs are marketed as combined dose tablet formulation in ratio of CIL:OLME 10:20. Literature survey revealed that no analytical method is reported for simultaneous estimation of CIL and OLME in combined dosage form. Hence it was proposed to develop simple, rapid, economical UV spectrophotometric methods for the simultaneous estimation of CIL and OLME in tablet dosage from [1] [2] [3] [4] [5] . 
Materials and method
Materials and instrunments
Cilnidipine and Olmesartan Medoxomil were obtained as gift samples from Ncube Pharmaceutical Pvt. Ltd., (Ahmadabad, India) and Intas pharmaceuticals Ltd. (Ahmadabad, India). The combined dosage form having brand name NEXOVAS O [Cilnidipine (10mg) and Olmesrtan Medoxomil (20mg)] were purchased from local market. AR grade methanol was procured from Chemco Chemicals Ltd., ( India). The Shimadzu UVVisible Spectrophotometer 1800 with matching pair of 1 cm quartz cuvettes. The spectral bandwidth is 0.5 nm. All the apparatus and instruments were calibrated and validated before starting the experimental work.
Method Preparation of standard solution
Stock solution of CIL (100 µg/ml) and OLME (100 µg/ml) were prepared in methanol and different standard solutions ranging from 10-60 µg/ml and 20-120 µg/ml were prepared by appropriately diluting stock solution for CIL and OLME, respectively.
Selection of wavelength for estimation of CIL and OLME
Absorbance spectrum of pure CIL (20 µg/ml) was scanned in the spectrum basic mode using the cursor function the absorbance corresponding to 352.92 nm (wavelength λ 1 , the wavelength of reasonable absorbance for CIL) was noted from the spectrum. Then the cursor function was moved along with peak curve and second wavelength 282.99 nm (λ 2 ) was selected, absorbance was noted at λ 2 . Again cursor function was moved with peak curve until the absorbance equal to that of absorbance at 282.99 nm was found. The wavelength obtained corresponding to absorbance value at 282.99 nm was 337.85 nm (λ 3 ). Absorbance spectrum of pure OLME (40 µg/ml) was also scanned in spectrum basic mode OLME showed some absorbance value at 282.99 nm (λ 2 ) while it does not showed any absorbance at 352.92 nm (λ 1 ), the absorbance value at 352.92 nm was due to CIL only in the combined mixture of both drugs and was selected for the measurement of CIL. The absorbance of various dilutions of CIL and OLME in diluents was measured at λ 2 and λ 3 . At these two wavelength absorbance difference of CIL at any concentration level was found to be zero while for OLME, absorbance difference was found to increase concomitantly as concentration was increase [6] [7] [8] [9] [10] [11] . 
Validation Linearity
Calibration curves were constructed by plotting absorbance vs. concentrations of CIL and OLME, at their respective detection wavelengths and the regression equations were calculated. The calibration curves were plotted over the six different concentrations in the range 10-60 µg/ml and 20-120 µg/ml for CIL and OLME, respectively ( Fig.3 and Fig.4) . The optical parameters and statistical parameters are depicted in Table 1 . 
Accuracy (% Recovery)
The accuracy of the method was determined by calculating recoveries of CIL and OLME by the standard addition method. Known amount of standard of CIL and OLME (50%, 100%, and 150%) were added to the sample solutions of tablet dosage forms. The amounts of CIL and OLME were estimated by regression equation. The results are shown in Table 4 . The values prove that the method is accurate.
Precision (Repeatability)
The precision was checked by repeatedly scanning (n = 6) standard solutions of CIL (20 µg/ml) and OLME (40 µg/ml). The RSD values were found to be below 2% which indicate that the proposed methods are repeatable ( Table 2) .
Intermediate Precision (Reproducibility)
The intermediate precision for the proposed method was determined by estimating standard solution of CIL (10, 30, 50 µg/ml) and OLME (20, 60, 100 µg/ml) for three times on the same day (intraday) and on three different days (interday). The results are reported in terms of relative standard deviation (RSD). The RSD values were found to be below 2% which indicate that the proposed methods are reproducible ( Table 2) .
Limit of detection (LOD) and limit of quantification (LOQ)
The LOD and LOQ of CIL and OLME were determined by using standard deviation of the response and slope approach as defined in International Conference on Harmonization (ICH) guidelines. The LOD and LOQ data are presented in (Table 2) . 
Procedure for the analysis of tablet formulation
Preparation of sample solution
Twenty tablets were weighed, average weight determined and finely powdered. Appropriate quantity of powder equivalent to 10 mg of CIL or 20 mg OLME was accurately weighed, transferred to a 10 ml volumetric flask and volume was made up to 10 ml with methanol and shaken vigorously for 15 minutes. The solution was then sonicated for 5 minutes and filtered through the Whatman filter paper no.41. Necessary dilutions of filtrate were made with methanol to get final concentration 20 µg/ml of CIL and 40 µg/ml of OLME. Absorbance of this solution was measured at 352.92 nm (λ 1 ) 282.99 nm ((λ 2 ), and 337.85 nm (λ 3 ). For CIL absorbance at 352.92 nm is considered and for OLME absorbance at 282.99 nm is subtracted from absorbance at 337.85 nm (A 337.85 -A 282.99 ) is considered. The values obtained were substituted in the regression equation to obtain concentrations of CIL and OLME. The results are shown in Table 3 [12] .
3.Results and discussion
Cilnidipine is new calcium channel antagonist used as antihypertensive agent. Linearity was obeyed in concentration range of 10-60 µg/ml and 20-120 µg/ml for CIL and OLME, respectively. As the values of % RSD of all precision study were within the acceptable limits (less than 2 %), the method provides good precision and reproducibility. The % RSD(less than 2 %) of accuracy study indicated that the method was accurate. Results of the recovery study were found to be within the acceptance criteria.
4.Conclusion
The proposed method is based on dual wavelength data processing and only requires measurement of absorbance at selected wavelengths. Interference studies revealed that the common excipients and other additives usually present in the tablet dosage forms did not interfere in the proposed method for estimation of both drugs. The proposed method was found to be simple, rapid, economical, accurate and precise. It can be useful for routine in process quality control and simultaneous estimation of CIL and OLME from their combined tablet dosage forms. 
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